Low-level Laser Therapy In Patients Research Articles

Low-Level Laser Therapy in Patients with Complaints of Tinnitus: A Clinical Study

Objective. The objective of the study was to investigate the effectiveness of low-level laser therapy (LLLT) in treating patients who were suffering from long-term complaints of tinnitus with well-understood etiology and who were not responding to conventional therapy in Qatar. Design. This is a prospective clinical study conducted during the period from May 2010 and February 2011. Setting. Audiology Clinic, Outpatient Department, Hamad General Hospital. Subjects and Methods. The study included 65 patients aged 15–76 years with chronic unilateral or bilateral tinnitus with a minimum duration of illness of one year. The investigation included 101 ears of 65 patients. A 5 mW laser with a wavelength of 650 nm was applied transmeatally for 20 minutes once daily for 3 months. The study was based on a face-to-face interview with a designed questionnaire that recorded the diagnosis of patients, clinical evaluation and audiometric test results, and side effects of low-level laser therapy (LLLT) and scored their symptoms loudness on five-point scale every two weeks. A decrease of one scale point regarding the loudness duration and degree of annoyance of tinnitus was accepted to represent an improvement; at the same time, a pure tone audiometric test was carried out and the results recorded. In addition, a record of the side effect was taken. Results. Over half of the patients (56.9%) had some form of improvement in their tinnitus symptoms. Mild improvement was reported in 33.8% of patients, moderate improvement was reported in 16.9%, and full improvement was reported in 6.15%. Of the patients who reported dizzy spells as a symptom of their tinnitus condition, 27.7% reported mild improvement and 16.9% reported full improvement. Common side effects of LLLT were noted among 20% of patients; however, all of them were mild and disappeared within a few days. Conclusion. Low-level laser therapy was found to be useful for treatment of chronic tinnitus.

Evaluation of low-level laser therapy in patients with acute and chronic temporomandibular disorders

The purpose of this study was to address the following question: among patients with acute or chronic temporomandibular disorders (TMD), does low-level laser therapy (LLLT) reduce pain intensity and improve maximal mouth opening? The sample comprised myogenic TMD patients (according Research Diagnostic Criteria for TMD). Inclusion criteria were: male/female, no age limit, orofacial pain, tender points, limited jaw movements and chewing difficulties. Patients with other TMD subtypes or associated musculoskeletal/rheumatologic disease, missing incisors teeth, LLLT contra-indication, and previous TMD treatment were excluded. According to disease duration, patients were allocated into two groups, acute (<6 months) and chronic TMD (≥ 6 months). For each patient, 12 LLLT sessions were performed (gallium-aluminum-arsenide; λ = 830 nm, P = 40 mW, CW, ED = 8 J/cm(2)). Pain intensity was recorded using a 10-cm visual analog scale and maximal mouth opening using a digital ruler (both recorded before/after LLLT). The investigators were previously calibrated and blinded to the groups (double-blind study) and level of significance was 5% (p < 0.05). Fifty-eight patients met all criteria, 32 (acute TMD), and 26 (chronic TMD). Both groups had a significant pain intensity reduction and maximal mouth opening improvement after LLLT (Wilcoxon test, p < 0.001). Between the groups, acute TMD patient had a more significant pain intensity reduction (Mann-Whitney test, p = 0.002) and a more significant maximal mouth opening improvement (Mann-Whitney test, p = 0.011). Low-level laser therapy can be considered as an alternative physical modality or supplementary approach for management of acute and chronic myogenic temporomandibular disorder; however, patients with acute disease are likely to have a better outcome.

Is Effect of Low-Level Laser Therapy in Patients with Burning Mouth Syndrome Result of a Placebo?

Photomedicine and Laser SurgeryVol. 29, No. 9 Letter to the EditorIs Effect of Low-Level Laser Therapy in Patients with Burning Mouth Syndrome Result of a Placebo?Domagoj Vukoja, Ivan Alajbeg, Vanja Vučićević Boras, Vlaho Brailo, Iva Z. Alajbeg, and Ana Andabak RoguljDomagoj VukojaDental Unit Zagreb Istok, Švarcova, Zagreb, Croatia.Search for more papers by this author, Ivan AlajbegDepartment of Oral Medicine, School of Dental Medicine, University of Zagreb, Zagreb, Croatia.Search for more papers by this author, Vanja Vučićević BorasDepartment of Oral Medicine, School of Dental Medicine, University of Zagreb, Zagreb, Croatia.Search for more papers by this author, Vlaho BrailoDepartment of Oral Medicine, School of Dental Medicine, University of Zagreb, Zagreb, Croatia.Search for more papers by this author, Iva Z. AlajbegDepartment of Prosthodontics, School of Dental Medicine, University of Zagreb, Zagreb, Croatia.Search for more papers by this author, and Ana Andabak RoguljDepartment of Oral Medicine, School of Dental Medicine, University of Zagreb, Zagreb, Croatia.Search for more papers by this authorPublished Online:6 Sep 2011https://doi.org/10.1089/pho.2011.3005AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View article"Is Effect of Low-Level Laser Therapy in Patients with Burning Mouth Syndrome Result of a Placebo?." , 29(9), pp. 647–648FiguresReferencesRelatedDetailsCited byNd:YAG photobiomodulation treatment in burning mouth syndrome: a pilot study8 February 2021 | Lasers in Dental Science, Vol. 5, No. 1Photobiomodulation in Oral Medicine Katayoun A.M. Kalhori, Farshid Vahdatinia, Mohammad Reza Jamalpour, Paolo Vescovi, Carlo Fornaini, Elisabetta Merigo, and Reza Fekrazad20 December 2019 | Photobiomodulation, Photomedicine, and Laser Surgery, Vol. 37, No. 12Effects of low-level laser therapy on burning mouth syndrome22 December 2016 | Journal of Oral Rehabilitation, Vol. 44, No. 2PBM. Theoretical and Applied Concepts of Adjunctive Use of LLLT/PBM Within Clinical Dentistry22 September 2017Interventions for treating burning mouth syndrome18 November 2016 | Cochrane Database of Systematic Reviews, Vol. 2016, No. 11Efficacy evaluation of clonazepam for symptom remission in burning mouth syndrome: a meta-analysis20 January 2016 | Oral Diseases, Vol. 22, No. 6Efficacy of low-level laser therapy for the treatment of burning mouth syndrome: a randomized, controlled trialJournal of Biomedical Optics, Vol. 20, No. 9Burning Mouth Syndrome. Update 5 February 2014 | The Journal of Dentists, Vol. 2, No. 1The Current Status of LLLT in the Field of Dental and Oral Surgery -In Anticipation of the Recent Trend and the Concept of LLLT-Nippon Laser Igakkaishi, Vol. 34, No. 4Treatment of Burning Mouth Syndrome with a Low-Level Energy Diode Laser: Response to Vukoja et al. Hui-Wen Yang and Yu-Feng Huang6 September 2011 | Photomedicine and Laser Surgery, Vol. 29, No. 9Response to Yang and Huang Ivan Alajbeg, Domagoj Vukoja, Vanja Vučićević Boras, Vlaho Brailo, Iva Z. Alajbeg, and Ana Andabak Rogulj6 September 2011 | Photomedicine and Laser Surgery, Vol. 29, No. 9 Volume 29Issue 9Sep 2011 InformationCopyright 2011, Mary Ann Liebert, Inc.To cite this article:Domagoj Vukoja, Ivan Alajbeg, Vanja Vučićević Boras, Vlaho Brailo, Iva Z. Alajbeg, and Ana Andabak Rogulj.Is Effect of Low-Level Laser Therapy in Patients with Burning Mouth Syndrome Result of a Placebo?.Photomedicine and Laser Surgery.Sep 2011.647-648.http://doi.org/10.1089/pho.2011.3005Published in Volume: 29 Issue 9: September 6, 2011Online Ahead of Print:April 14, 2011PDF download

The Prevention of Induced Oral Mucositis with Low-Level Laser Therapy in Bone Marrow Transplantation Patients: A Randomized Clinical Trial

Patients who have received high doses of chemotherapy, either alone or in combination with total body irradiation often cite oral mucositis (OM) as the most debilitating side effect. The aim of this study was to investigate the clinical effects of low-level laser therapy (LLLT) on the prevention of conditioning-induced OM in hematopoietic stem cell transplantation (HSCT). We randomized 42 patients who underwent autologous or allogeneic HSCT. A low-level InGaAlP diode laser was used, emitting light at 660 nm, 40 mW, and 4 J/cm(2). An evaluation of OM was carried out using the World Health Organization scale. In the LLLT group, 57.1% of patients had an OM grade 0, 9.6% had grade 1, and 33.3% had grade 2, whereas in the control group, only 4.8% of patients were free of OM (grade 0). Our results indicate that the preventive use of LLLT in patients who have undergone HSCT is a powerful instrument in reducing OM incidence.

Low level laser therapy for nonspecific low-back pain

Low-back pain (LBP) is a major health problem and a major cause of medical expenses and disablement. Low level laser therapy (LLLT) can be used to treat musculoskeletal disorders such as back pain. To assess the effects of LLLT in patients with non-specific LBP. We searched CENTRAL (The Cochrane Library 2005, Issue 2), MEDLINE, CINAHL, EMBASE, AMED and PEDro from their start to November 2007 with no language restrictions. We screened references in the included studies and in reviews and conducted citation tracking of identified RCTs and reviews using Science Citation Index. We also contacted content experts. Randomised controlled clinical trials (RCTs) investigating LLLT to treat non-specific low-back pain were included. Two authors independently assessed methodological quality using the criteria recommended by the Cochrane Back Review Group and extracted data. Studies were qualitatively and quantitatively analysed according to Cochrane Back Review Group guideline. Seven heterogeneous English language RCTs with reasonable quality were included. Three small studies (168 people) separately showed statistically significant but clinically unimportant pain relief for LLLT versus sham therapy for sub-acute and chronic low-back pain at short-term and intermediate-term follow-up (up to six months). One study (56 people) showed that LLLT was more effective than sham at reducing disability in the short term. Three studies (102 people) reported that LLLT plus exercise were not better than exercise, with or without sham in the short-term in reducing pain or disability. Two studies (90 people) reported that LLLT was not more effective than exercise, with or without sham in reducing pain or disability in the short term. Two small trials (151 people) independently found that the relapse rate in the LLLT group was significantly lower than in the control group at the six-month follow-up. No side effects were reported. Based on the heterogeneity of the populations, interventions and comparison groups, we conclude that there are insufficient data to draw firm conclusions on the clinical effect of LLLT for low-back pain. There is a need for further methodologically rigorous RCTs to evaluate the effects of LLLT compared to other treatments, different lengths of treatment, wavelengths and dosages.

Consensus Agreement on the Design and Conduct of Clinical Studies with Low-Level Laser Therapy and Light Therapy for Musculoskeletal Pain and Disorders

Consensus Agreement on the Design and Conduct of Clinical Studies with Low-Level Laser Therapy and Light Therapy for Musculoskeletal Pain and Disorders

Chemotherapy- and Radiotherapy-Induced Oral Mucositis: Review of Preventive Strategies and Treatment

Oral mucositis is a frequently encountered and potentially severe complication associated with administration of chemotherapy and radiotherapy. Although many pharmacologic interventions have been used for the prevention and treatment of oral mucositis, there is not one universally accepted strategy for its management. Most preventive and treatment strategies are based on limited, often anecdotal, clinical data. Basic oral hygiene and comprehensive patient education are important components of care for any patient with cancer at risk for development of oral mucositis. Nonpharmacologic approaches for the prevention of oral mucositis include oral cryotherapy for patients receiving chemotherapy with bolus 5-fluorouracil, and low-level laser therapy for patients undergoing hematopoietic stem cell transplantation. Chlorhexidine, amifostine, hematologic growth factors, pentoxifylline, glutamine, and several other agents have all been investigated for prevention of oral mucositis. Results have been conflicting, inconclusive, or of limited benefit. Treatment of established mucositis remains a challenge and focuses on a palliative management approach. Topical anesthetics, mixtures (also called cocktails), and mucosal coating agents have been used despite the lack of experimental evidence supporting their efficacy. Investigational agents are targeting the specific mechanisms of mucosal injury; among the most promising of these is recombinant human keratinocyte growth factor.

Low Level Laser Therapy for Tendinopathy. Evidence of A Dose–Response Pattern

To investigate whether low-level laser therapy (LLLT) can reduce pain from tendinopathy, we performed a review of randomized placebo-controlled trials with LLLT for tendinopathy. The literature search for trials using LLLT published after 1980 was conducted on Medline, Embase, and the Cochrane Library, together with a hand-search of physiotherapy journals in English and Scandinavian languages. Validity assessment of each trial was done according to predefined criteria for location-specific dosage and irradiation of the skin directly overlying the affected tendon. The literature search identified 78 randomized controlled trials with LLLT, of which 20 included tendinopathy. Seven trials were excluded for not meeting validity criteria on treatment procedure or trial design. Twelve of the remaining 13 trials investigated the effect of LLLT for patients with subacute and chronic tendinopathy, and provided a pooled mean effect of 21% [95% confidence interval (CI) 5.9–36.1]. If results from only the nine trials adhering to assumed optimal treatment parameters were included, the mean effect over placebo increased to 32% (95% CI: 23.0–41.0). LLLT can reduce pain in subacute and chronic tendinopathy if a valid treatment procedure and location-specific dose is used.